- Report
- February 2024
- 70 Pages
Vietnam
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
Iran
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
Russia
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
Australia
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
Japan
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 85 Pages
North America
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 181 Pages
Europe
From €4284EUR$4,750USD£3,673GBP
- Report
- October 2022
- 70 Pages
Africa
From €4284EUR$4,750USD£3,673GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,157USD£3,106GBP

Insulin Glulisine is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose for energy. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes.
Insulin Glulisine is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, control blood sugar levels, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Glulisine market include Eli Lilly, Novo Nordisk, Sanofi, and Biocon. Show Less Read more